UniProtKB/Swiss-Prot P69892 : Variant p.His64Tyr
Hemoglobin subunit gamma-2
Gene: HBG2
Feedback ?
Variant information
Variant position:
64
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Histidine (H) to Tyrosine (Y) at position 64 (H64Y, p.His64Tyr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (H) to large size and aromatic (Y)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In TNCY; hemoglobin Osaka; the presence of a tyrosine causes the formation of a covalent link with heme iron, so that the iron is stabilized in the ferric form; when this occurs methemoglobin is formed, oxygen can no longer bind to heme and cyanosis occurs.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
64
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
147
The length of the canonical sequence.
Location on the sequence:
DSFGNLSSASAIMGNPKVKA
H GKKVLTSLGDAIKHLDDLKG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 147
Hemoglobin subunit gamma-2
Domain
3 – 147
Globin
Binding site
64 – 64
distal binding residue
Modified residue
45 – 45
Phosphoserine
Modified residue
51 – 51
Phosphoserine
Modified residue
53 – 53
Phosphoserine
Modified residue
60 – 60
N6-acetyllysine
Modified residue
83 – 83
N6-acetyllysine
Helix
59 – 75
Literature citations
Hb F-M-Osaka or alpha 2G gamma 2(63)(E7)His-->Tyr in a Caucasian male infant.
Glader B.E.; Zwerdling D.; Kutlar F.; Kutlar A.; Wilson J.B.; Huisman T.H.J.;
Hemoglobin 13:769-773(1989)
Cited for: VARIANT TNCY TYR-64;
Neonatal cyanosis due to a novel fetal hemoglobin: Hb F-Circleville [Ggamma63(E7)His-->Leu, CAT>CTT].
Dainer E.; Shell R.; Miller R.; Atkin J.F.; Pastore M.; Kutlar A.; Zhuang L.; Holley L.; Davis D.H.; Kutlar F.;
Hemoglobin 32:596-600(2008)
Cited for: FUNCTION; VARIANT TNCY LEU-64; CHARACTERIZATION OF VARIANT TNCY TYR-64;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.